Table 2.
Current pharmacological and device trials in HFpEF patients focusing on biomarker levels, quality of life, and cognitive function
| Study name | Intervention | Study size | Primary endpoint | Identifier |
|---|---|---|---|---|
| Soluble guanylyl cyclase stimulators and activators | ||||
| SERENADE | Macitentan | 300 | Change in NT-proBNP levels | NCT03153111 |
| VITALITY | Vericiguat | 735 | Change in QOL | NCT03547583 |
| Inorganic nitrates/nitrites | ||||
| PMED | Oral nitrate | 120 | Change in nitrate/nitrite level, microbiome | NCT02980068 |
| Angiotensin receptor neprilysin inhibitor | ||||
| PERSPECTIVE | LCZ696 | 520 | Change in cognitive function | NCT02884206 |
| PARALLAX | LCZ696 | 2500 | Change in NT-proBNP levels | NCT03066804 |
| Sodium glucose cotransporter-2 inhibitors | ||||
| PRESERVED-HF | Dapagliflozin | 320 | Change in NT-proBNP levels | NCT03030235 |
| ERADICATE-HF | Ertugliflozin | 36 | Change in proximal sodium reabsorption | NCT03416270 |
| Restoring mitochondrial energy | ||||
| Elamipretide in patients hospitalized with congestion due to HF | Elamipretide | 300 | Change in NT-pro-BNP levels | NCT02914665 |
| Device therapy | ||||
| CCM-HFpEF | CCM | 50 | Change in QOL | NCT03240237 |
QOL quality of life, NT-pro-BNP N-terminal-pro hormone B-type natriuretic peptide